Fentanyl-Ropivacaine-0.9% Nacl (fentanyl citrate/ropivacaine HCl/sodium chloride 0.9%/PF)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Ropivacaine hydrochloride is a long-acting local anesthetic of the amide type.
Fentanyl is a synthetic phenylpiperidine-derivative opiate agonist.
Ropivacaine hydrochloride is a long-acting local anesthetic of the amino amide class. Local anesthetics block the generation and conduction of nerve impulses possibly by increasing the threshold for electrical excitation, slowing the propagation of the nerve impulse, and reducing the rate of rise of the action potential. Progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers.
Unlike most other local anesthetics, the addition of epinephrine has no substantial effect on the onset time or duration of ropivacaine. The onset, depth, and duration of sensory block with ropivacaine are generally similar to bupivacaine; however, the depth and duration of motor block are less than bupivacaine.
Ropivacaine is structurally related to bupivacaine; however, unlike bupivacaine, which exists in its racemic form, ropivacaine is an S-enantiomer. Ropivacaine is less lipophilic and less likely to penetrate large myelinated nerve fibers than bupivacaine. These physiochemical and stereoselective differences are thought to contribute to the lower cardiac and CNS toxicity of ropivacaine compared with bupivacaine.
Fentanyl is a potent analgesic that shares the actions of the opiate agonists. Fentanyl interacts predominately with the opioid mu receptor; mu receptor binding sites are distributed in the human brain, spinal cord, and other tissues. The agonist activity of fentanyl at the mu receptor can also result in suppression of opioid withdrawal (and antagonist activity can result in precipitation of withdrawal).
Fentanyl mediates respiratory depression by direct action on brain stem respiratory centers. Fentanyl also causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and in the duodenum. Other opioid-related effects may include a reduction in biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.
Cardiovascular effects of fentanyl include peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension. Opioid agonists have been shown to have a variety of effects on the secretion of hormones including adrenocorticotropic hormone (ACTH), cortisol, luteinizing hormone (LH), prolactin, growth hormone (GH), insulin, glucagon, and thyroid stimulating hormone (TSH).
Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility.
Fentanyl is well absorbed percutaneously following topical application of fentanyl transdermal system to a flat surface on the upper torso. The amount of fentanyl released from the system is proportional to the surface area of the system; however, the actual amount of drug delivered to the skin exhibits interindividual variation. Peak concentration is attained within 20-72 hours after initial application.
Serum concentrations increase with the first 2 transdermal system applications; steady state is reached by the end of the second 72-hour application and is maintained during continued use at the same dosage. Application of heat over the transdermal system increases mean exposure and peak plasma concentrations by 120 and 61%, respectively. Following use of fentanyl transdermal system in non-opioid-tolerant children, plasma fentanyl concentrations in children 1.5-5 years of age were about twice the concentrations achieved in adults; however, pharmacokinetic parameters in older children were similar to those in adults.
Fentanyl is well absorbed transmucosally following intrabuccal administration as fentanyl citrate transmucosal lozenge or buccal tablet. Substantial pharmacokinetic differences exist among the transmucosal immediate-release preparations; these preparations must not be substituted on a mcg-for-mcg basis. Bioavailability of the transmucosal lozenge averages about 50%; generally, approximately 25% of the drug is absorbed rapidly from the buccal mucosa and the remaining portion is swallowed with saliva and then absorbed slowly from the GI tract.
Bioavailability of the buccal tablet averages about 65%. Generally, approximately 50% of the drug is absorbed rapidly from the buccal mucosa and the remaining portion is swallowed with saliva and then absorbed slowly from the GI tract. The time required for the buccal tablet to fully disintegrate does not appear to affect early systemic drug exposure.
When fentanyl is administered as a buccal tablet rather than a transmucosal lozenge, a larger fraction of the administered dose is absorbed transmucosally (48% versus 22%), peak plasma concentration is achieved earlier (47 versus 91 minutes), and systemic exposure is approximately 30-50% greater.
The onset of action following IV administration of fentanyl is rapid; peak analgesia occurs within several minutes and the duration of analgesia is 30-60 minutes after a single dose of up to 100 mcg. Following IM administration of fentanyl citrate, the onset of action occurs within about 7-15 minutes and the duration of action is 1-2 hours. Respiratory depressant effects may persist longer than analgesia.
Residual effects of one dose of fentanyl citrate may potentiate the effects of subsequent doses. It has been suggested that redistribution is the main cause of the brief analgesic effect of fentanyl.
Fentanyl is highly lipophilic. Fentanyl crosses the placenta and is distributed into breast milk. Approximately 80-85% of the drug is protein-bound, principally to alpha1-acid glycoprotein.
Fentanyl is metabolized extensively in the liver and the intestinal mucosa via cytochrome P-450 (CYP) 3A4 to norfentanyl and other inactive metabolites. Transdermally administered fentanyl does not appear to be metabolized in the skin. Fentanyl is principally eliminated in urine, as inactive metabolites and to a lesser extent (<10%) as unchanged drug.
The terminal half-life of the transmucosal lozenges is about 7 hours. The terminal elimination half-life of parenteral fentanyl is 219 minutes.
Generic name: fentanyl citrate/ropivacaine HCl/sodium chloride 0.9%/PF
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Fentanyl-Ropivacaine-0.9% Nacl
Indications
No indications are available for this drug.
Dosing
Dosage of ropivacaine hydrochloride is expressed in terms of ropivacaine hydrochloride. Dosage of ropivacaine hydrochloride varies with the anesthetic procedure, degree of anesthesia required, surgical site, and individual patient response. The smallest dose and lowest concentration required to produce the desired effect should be used. Rapid administration of a large single dose should be avoided. The manufacturer's dosage recommendations are based on the expected average dosage range necessary to produce a successful block in adults and should be used as a general guideline.
Dosage of fentanyl and fentanyl citrate is expressed in terms of fentanyl. The drug should be given at the lowest effective dosage and for the shortest duration of therapy consistent with the treatment goals of the patient. Reduced dosage is indicated initially in poor-risk patients and geriatric patients. Dosage of fentanyl should be titrated carefully in geriatric patients. If concomitant therapy with other CNS depressants is required, the lowest effective dosages and shortest possible duration of concomitant therapy should be used.
Ropivacaine hydrochloride may be administered by epidural block, peripheral nerve block (e.g., brachial plexus block), or local infiltration. The manufacturer states that ropivacaine should not be used for obstetrical paracervical block, retrobulbar block, or spinal anesthesia (subarachnoid block), and should not be administered using the Bier block technique (IV regional anesthesia).
Local anesthetics, including ropivacaine, have been administered by continuous intra-articular infusion+ (e.g., for control of postoperative pain); however, such use has been associated with chondrolysis. (See Cautions: Musculoskeletal Effects in the Local Anesthetics, Parenteral, General Statement 72:00.)
To prevent intravascular or subarachnoid injection of a large epidural dose of ropivacaine hydrochloride, a test dose (e.g., 3-5 mL of a short-acting local anesthetic solution containing epinephrine) should be injected prior to administering the total dose. When clinical conditions permit, use of a test dose solution that contains epinephrine should be considered to detect inadvertent intravascular injection. The test dose should be repeated if the epidural catheter is displaced. An adequate time for onset of anesthesia should be allowed following administration of each test dose.
Fentanyl citrate injection is administered parenterally (IV or IM).
Fentanyl citrate buccal tablets and transmucosal lozenges are administered intrabuccally. Once an effective dose is determined, the buccal tablets may be administered sublingually as an alternate route of administration.
Fentanyl transdermal systems are applied topically to the skin.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed to date with ropivacaine hydrochloride.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to ropivacaine hydrochloride or other local anesthetics of the amide type.
*Opioid non-tolerant patients: Life-threatening respiratory depression and death could occur at any dose.
*Significant respiratory depression.
*Patients with substantial respiratory depression, especially in settings where adequate monitoring and equipment for resuscitation are not available; in patients with acute or severe bronchial asthma; and in those with known or suspected paralytic ileus.
*Known hypersensitivity to fentanyl or any ingredient or component of the respective formulation.
*Fentanyl Transdermal Systems:: Managment of mild pain, acute or intermittent pain, or in patients that require analgesia for a short period of time.
*Fentanyl Transdermal Systems, Transmucosal Lozenges, and Buccal Tablets:Acute or postoperative pain including headache/migraine and dental pain, or acute pain in the emergency department.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects reported in 5% or more of patients receiving ropivacaine hydrochloride in clinical studies include hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
The most common adverse effects reported with parenteral administration of fentanyl include respiratory depression, apnea, rigidity, and bradycardia.
The most common adverse effects reported with use of fentanyl transdermal system (>=5% incidence) include nausea, vomiting, somnolence, dizziness, insomnia, constipation, hyperhidrosis, fatigue, feeling cold, anorexia, headache, and diarrhea.
The most common adverse effects reported with use of fenanyl buccal tablets (>=10% incidence) include nausea, dizziness, vomiting, fatigue, anemia, constipation, peripheral edema, asthenia, dehydration, and headache.
The most common adverse effects reported with use of fentanyl transmucosal lozenges (>=5% incidence) include nausea, dizziness, somnolence, vomiting, asthenia, headache, dyspnea, constipation, anxiety, confusion, depression, rash, and insomnia.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
The manufacturer states that efficacy and safety of ropivacaine have not been established in pediatric patients; however, the drug has been used in children for postoperative analgesia.
Safety and efficacy of parenteral fentanyl citrate and fentanyl transdermal systems have not been established in pediatric patients <2 years of age.
Safety and efficacy of transmucosal lozenges have not been established in pediatric patients <16 years of age. Safety and efficacy of buccal tablets have not been established in pediatric patients <18 years of age.
To reduce the potential for accidental ingestion, carefully select application sites in young children receiving transdermal fentanyl therapy and monitor the system for proper adhesion over the period of application. Transdermal systems and transmucosal immediate-release preparations (transmucosal lozenges, buccal tablets) contain fentanyl in amounts that can be fatal to a child. Fatal respiratory depression can occur if a transdermal system is accidentally or deliberately applied or ingested by a child or adolescent; choking can occur if the system is ingested. There is a high risk of respiratory depression if a child accidentally ingests a transmucosal immediate-release preparation.
Category B.
There are no adequate and well-controlled studies of ropivacaine in pregnant women. Animal reproductive studies have not shown any evidence of teratogenicity or adverse developmental effects; however, maternal toxicity has been observed. Local anesthetics rapidly cross the placenta during epidural administration and can cause varying degrees of maternal, fetal, and neonatal toxicity. Ropivacaine should be used during pregnancy only if the benefits outweigh the risks.
Maternal hypotension has occurred with the use of ropivacaine for obstetrical pain relief. (See Cautions in the Local Anesthetics, Parenteral, General Statement 72:00.)
Available data in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.
In animal reproduction studies, fentanyl administration to pregnant rats during organogenesis was embryocidal at doses within the range of the human recommended dosing and when administered during gestation through lactation resulted in reduced pup survival and developmental delays at doses within the range of the human recommended dosing. No evidence of malformations noted in animal studies completed to date.
Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates. There are insufficient data to support the use of fentanyl in labor or delivery and therefore such use is not recommended.
Transient neonatal muscular rigidity reported in infants whose mothers received IV fentanyl during labor.
Prolonged maternal use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome; withdrawal syndrome in neonates may be life-threatening and requires management according to protocols developed by neonatology experts. Syndrome presents with irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
Ropivacaine is distributed into milk in rats; it is not known whether the drug or its metabolites are distributed into human milk. Based on the milk to plasma concentration ratio and estimated exposures in rats, infant exposure to ropivacaine from breastfeeding is expected to be far less than the exposure in utero. Ropivacaine should be used with caution in nursing women.
Fentanyl is distributed into human milk.
Manufacturers of fentanyl transdermal system and transmucosal immediate-release fentanyl preparations (used only in opioid-tolerant patients) state these preparations should not be used in nursing women because of the potential for serious adverse effects in nursing infants.
There is a potential risk of sedation and respiratory depression in nursing infants; monitor breastfeeding infants for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
Geriatric patients may have increased sensitivity to fentanyl. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
In clinical studies of ropivacaine, 27% of patients receiving the drug were 65 years of age or older and 4% were 75 years of age or older. The drug was found to be safe and effective in these patients.
Differences in various pharmacodynamic measures of ropivacaine have been observed with increasing age. In one clinical study, the upper level of analgesia increased with age, the maximum decrease of mean arterial pressure declined with age for the first hour following epidural administration, and the intensity of motor blockade increased with age.
Because ropivacaine and its metabolites are substantially excreted by the kidneys, the risk of toxic reactions to the drug may be greater in patients with renal impairment. Dosage should therefore be selected with caution in geriatric patients, usually starting at the lower end of the dosage range, since such patients are more likely to have decreased hepatic, renal, and/or cardiac function as well as concomitant illnesses. The manufacturer states that it may be useful to monitor renal function in geriatric patients.
Pharmacokinetics of fentanyl may be altered in geriatric patients, increasing risk of life-threatening respiratory depression. Monitor closely for sedation and respiratory depression, particularly during initiation or titration of therapy and when other respiratory depressants are used concomitantly.
Use caution when titrating dosage. Renal clearance of fentanyl may be reduced. Geriatric patients may be more sensitive to effects of fentanyl.
Clinical studies of fentanyl transdermal system did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger subjects. However, a study reported that the pharmacokinetics of fentanyl transdermal system in geriatric patients are not substantially different than that in younger adults, although peak serum concentrations tended to be lower and mean half-life was prolonged in geriatric patients. Dosages of transmucosal lozenges (following titration) are generally about 200 mcg lower in geriatric patients than in younger adults. Dosages of buccal tablets (following titration) are slightly lower in geriatric patients than in younger adults. Increased frequency of certain adverse effects (e.g., vomiting, constipation, abdominal pain) reported in geriatric patients compared with younger adults receiving buccal tablets.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.